Navigation Links
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
Date:5/8/2008

cluding patients with moderate to severe chronic pain due to osteoarthritis showed that the efficacy and tolerability of ALO-01 was comparable to marketed extended-release morphine sulfate capsules (KADIAN(R) Capsules). Additionally, when ALO-01 was taken as directed, the sequestered naltrexone had no impact on either pain relief or tolerability.

"The undertreatment of chronic pain and the abuse of prescription opioids are both serious health problems that require urgent attention," said Joseph Stauffer, DO, Chief Medical Officer of Alpharma Pharmaceuticals. "As the data suggest, ALO-01 has the potential to address issues of abuse liability while effectively treating patients with chronic pain."

On April 21, Alpharma announced that it withdrew its New Drug Application (NDA) for ALO-01 and plans to resubmit a revised application in approximately two months. While the initial NDA submission qualified for a priority review, certain technical issues around data presentation prevented a complete evaluation by the U.S. Food and Drug Administration (FDA) within the six month time period permissible for a priority review. Alpharma expects to address the submission issues and re-qualify for priority review in its resubmission, and continues to anticipate a first quarter 2009 launch following approval.

Pain is a serious, undertreated public health problem in the United States, with 19 percent of American adults reporting chronic pain and 34 percent reporting recurrent pain.(1A) Opioids provide effective pain management and are especially useful in treating appropriately selected patients with moderate to severe chronic pain who have not responded adequately to other pain management therapies.(2,3A) However, prescription opioid abuse has escalated along with increased legitimate use in pain management.(1B,4A,5) In fact, 70 percent of people who have abused opioids got them from friends and relatives (by stealing, buying, or being given them).(6) Because of
'/>"/>

SOURCE Alpharma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
4. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will present at the 16th Annual B. Riley ... 13, 2015. The conference will be held May 12-14, 2015 ... Heska management will be available during the day on ...
(Date:5/1/2015)... , May 1, 2015 Braeburn ... its current therapeutic focus beyond addiction and ... psychiatric disorders. Braeburn has acquired an implantable, ... antipsychotic risperidone for treatment of schizophrenia from ... acquires global rights to other potential applications ...
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... LYNDHURST, N.J., Aug. 30 A molecular,diagnostic ... 85,developmental disorders affecting children now is commercially ... testing and,reimbursement by leading health plans across ... ), the nation,s leading provider of diagnostic,testing, ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... commercializing proprietary product candidates principally,for use in ... completed patient,enrollment in a pivotal Phase III ... intravenous acetaminophen (IV,acetaminophen), for the treatment of ...
Cached Medicine Technology:Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 2Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 3Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 2Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 3Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 4Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule 5
(Date:5/4/2015)... Missouri (PRWEB) May 04, 2015 “St. ... as the “Gateway to the West,” so it is ... for Veterans Program”, says Dr. Ben Litalien, Chief Development ... Franchise Association’s VetFran program and will provide veterans with ... , Zerorez® is proud to have a number of ...
(Date:5/3/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, ... reached the 2,000 ‘Like’ mark on their Facebook page. ... that educate the patients on the many services the ... as well as current events. , Women’s Excellence has ... Facebook, Twitter, Google +, Pinterest, Instagram and You Tube. ...
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... CA (PRWEB) May 02, 2015 ProText Kinetic ... for use in Final Cut Pro X. ProText Kinetic ... use in Final Cut Pro X . Easily ... keyframe with Pixel Film Studios' ProText Kinetic 2. , Using ... Start by staggering two ProText Kinetic presets in the FCPX ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2
... to Medicare payments are intended to accurately and equitably ... incurred by hospitals and individual health care practitioners, but ... to how their adjustments are calculated, finds a new ... of exceptions strongly suggests that the mechanisms underlying the ...
... advocacy organizations from India, Australia and the United States ... for the Study of Lung Cancer (IASLC) to send ... July 3-7 in Amsterdam. The winners are: ... Foundation is the premier organization for lung health in ...
... treatment for patients with advanced non-small cell lung ... cytotoxic chemotherapy drugs. The combination, however, comes with ... report that a combination of two molecularly-targeted agents ... "These results seem to be better than ...
... BOSTONScientists at Dana-Farber Cancer Institute have identified an ... breast cancer cells enriched in triple-negative breast tumors, ... to current therapies. Kornelia Polyak, MD, PhD, ... found that a large proportion of cells within ...
... Reporter , WEDNESDAY, June 1 (HealthDay News) -- Beta blockers ... by millions of people -- may eventually have a role ... One study suggests that women who are already taking beta ... breast cancer at an earlier stage of the disease and ...
... heart failure, an implanted mechanical pump known as a ... treatment. Even though the technology involves risks, few patients ... "what ifs" before surgery takes place. In the June ... of Mayo Clinic researchers found that careful discussions at ...
Cached Medicine News:Health News:Medicare should employ new data sources, methods to ensure accuracy of geographic adjustments to payments 2Health News:Medicare should employ new data sources, methods to ensure accuracy of geographic adjustments to payments 3Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 2Health News:5 advocacy organizations win travel awards to attend World Conference on Lung Cancer in Amsterdam 3Health News:Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients 2Health News:Scientists identify overactive genes in aggressive breast cancers 2Health News:Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes 2Health News:Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes 3Health News:Mayo Clinic finds discussion of end-of-life care helps heart to patients and families 2
Round serrated handle, dull finish....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: